WARNING: This product is for research use only, not for human or veterinary use.
Hodoodo CAT#: H413637
CAS#: 69376-27-8 (HCl)
Description: Dextrorphan HCl is the dextro form of levorphanol. It acts as a noncompetitive NMDA receptor antagonist, among other effects, and has been proposed as a neuroprotective agent. It is also a metabolite of DEXTROMETHORPHAN.
Hodoodo Cat#: H413637
Name: Dextrorphan HCl
CAS#: 69376-27-8 (HCl)
Chemical Formula: C17H24ClNO
Exact Mass: 293.15
Molecular Weight: 293.840
Elemental Analysis: C, 69.49; H, 8.23; Cl, 12.06; N, 4.77; O, 5.44
This product is not in stock, which may be available by custom synthesis.
For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge).
Quote less than 1g will not be provided. To request quote, please email to sales @hodoodo.com or click below button.
Note: Price will be listed if it is available in the future.
Related CAS #: 69376-27-8 (HCl) 125-73-5 (free base) 143-98-6 (tartrate)
Synonym: Dextrorphan HCl; Ro1-6794; Ro-1-6794; Ro 1-6794; Dextrorphan hydrochloride
IUPAC/Chemical Name: Morphinan-3-ol, 17-methyl-, hydrochloride, (9alpha,13alpha,14alpha)-
InChi Key: MKMAMQPDRUXVSS-BDURURIASA-N
InChi Code: InChI=1S/C17H23NO.ClH/c1-18-9-8-17-7-3-2-4-14(17)16(18)10-12-5-6-13(19)11-15(12)17;/h5-6,11,14,16,19H,2-4,7-10H2,1H3;1H/t14-,16-,17-;/m0./s1
SMILES Code: [H][C@@]12CCCC[C@@]13C4=CC(O)=CC=C4C[C@]2([H])N(C)CC3.[H]Cl
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: To be determined
Shelf Life: >2 years if stored properly
Drug Formulation: To be determined
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
More Info:
| Biological target: | |
| In vitro activity: | |
| In vivo activity: |
The following data is based on the product molecular weight 293.84 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
| 5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
| 10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
| 50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
| Formulation protocol: | |
| In vitro protocol: | |
| In vivo protocol: |
1: Albers GW, Atkinson RP, Kelley RE, Rosenbaum DM. Safety, tolerability, and pharmacokinetics of the N-methyl-D-aspartate antagonist dextrorphan in patients with acute stroke. Dextrorphan Study Group. Stroke. 1995 Feb;26(2):254-8. doi: 10.1161/01.str.26.2.254. PMID: 7831698.
2: Cleveland PA, Teller S, Kachevsky V, Pinili E, Evans R, Modi MW. Dose- dependent and time-dependent pharmacokinetics in the dog after intravenous administration of dextrorphan. Drug Metab Dispos. 1991 Jan-Feb;19(1):245-50. PMID: 1673409.
3: Muir KW, Lees KR. Clinical experience with excitatory amino acid antagonist drugs. Stroke. 1995 Mar;26(3):503-13. doi: 10.1161/01.str.26.3.503. PMID: 7886734.
4: Nakashima D, Takama H, Ogasawara Y, Kawakami T, Nishitoba T, Hoshi S, Uchida E, Tanaka H. Effect of cinacalcet hydrochloride, a new calcimimetic agent, on the pharmacokinetics of dextromethorphan: in vitro and clinical studies. J Clin Pharmacol. 2007 Oct;47(10):1311-9. doi: 10.1177/0091270007304103. Epub 2007 Jul 24. PMID: 17652181.
5: Ciccone PE, Ramabadran K, Jessen LM. Potential interactions of methylphenidate and atomoxetine with dextromethorphan. J Am Pharm Assoc (2003). 2006 Jul-Aug;46(4):472-8. doi: 10.1331/154434506778073600. PMID: 16913391.
6: Tortella FC, Robles L, Witkin JM, Newman AH. Novel anticonvulsant analogs of dextromethorphan: improved efficacy, potency, duration and side-effect profile. J Pharmacol Exp Ther. 1994 Feb;268(2):727-33. PMID: 8113984.
7: Rockhold RW, Byrne M, Sprabery S, Bennett JG. Urethane anesthesia reverses the protective effect of noncompetitive NMDA receptor antagonists against cocaine intoxication. Life Sci. 1994;54(5):321-30. doi: 10.1016/0024-3205(94)00788-8. PMID: 8289593.
8: Lou HG, Yuan H, Ruan ZR, Jiang B. Simultaneous determination of paracetamol, pseudoephedrine, dextrophan and chlorpheniramine in human plasma by liquid chromatography-tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci. 2010 Mar 1;878(7-8):682-8. doi: 10.1016/j.jchromb.2010.01.005. Epub 2010 Jan 18. PMID: 20133213.
9: Grözinger M, Dragicevic A, Hiemke C, Shams M, Müller MJ, Härtter S. Melperone is an inhibitor of the CYP2D6 catalyzed O-demethylation of venlafaxine. Pharmacopsychiatry. 2003 Jan;36(1):3-6. doi: 10.1055/s-2003-38084. PMID: 12649767.
10: Amchin J, Ereshefsky L, Zarycranski W, Taylor K, Albano D, Klockowski PM. Effect of venlafaxine versus fluoxetine on metabolism of dextromethorphan, a CYP2D6 probe. J Clin Pharmacol. 2001 Apr;41(4):443-51. doi: 10.1177/00912700122010159. PMID: 11304901.
